RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Basilea Pharmaceutica AG Allschwil Stock

Basilea Pharmaceutica AG Allschwil EBIT 2024

Basilea Pharmaceutica AG Allschwil EBIT

42.08 M CHF

Ticker

BSLN.SW

ISIN

CH0011432447

WKN

A0B9GA

In 2024, Basilea Pharmaceutica AG Allschwil's EBIT was 42.08 M CHF, a 119.13% increase from the 19.21 M CHF EBIT recorded in the previous year.

The Basilea Pharmaceutica AG Allschwil EBIT history

YEAREBIT (undefined CHF)
2029e25.24
2028e54.52
2027e81
2026e79.41
2025e51.04
2024e42.08
202319.21
202218.54
20211.17
2020-23.26
2019-17.2
2018-24.1
2017-17.05
2016-43.89
2015-61.49
2014-41.83
2013-33.3
2012-50.8
2011-57.3
2010-16.5
2009-120.3
2008-152.5
2007-136.5
2006-87.9
2005-50.8
2004-75.7

Basilea Pharmaceutica AG Allschwil Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Basilea Pharmaceutica AG Allschwil, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Basilea Pharmaceutica AG Allschwil from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Basilea Pharmaceutica AG Allschwil’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Basilea Pharmaceutica AG Allschwil. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Basilea Pharmaceutica AG Allschwil’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Basilea Pharmaceutica AG Allschwil’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Basilea Pharmaceutica AG Allschwil’s growth potential.

Basilea Pharmaceutica AG Allschwil Revenue, EBIT and net profit per share

DateBasilea Pharmaceutica AG Allschwil RevenueBasilea Pharmaceutica AG Allschwil EBITBasilea Pharmaceutica AG Allschwil Net Income
2029e146.14 M undefined25.24 M undefined24.93 M undefined
2028e190.05 M undefined54.52 M undefined54.28 M undefined
2027e234.89 M undefined81 M undefined77.74 M undefined
2026e254.81 M undefined79.41 M undefined68.69 M undefined
2025e222.44 M undefined51.04 M undefined46.6 M undefined
2024e204.07 M undefined42.08 M undefined51.88 M undefined
2023157.63 M undefined19.21 M undefined10.45 M undefined
2022147.77 M undefined18.54 M undefined12.15 M undefined
2021148.12 M undefined1.17 M undefined-6.83 M undefined
2020127.63 M undefined-23.26 M undefined-14.72 M undefined
2019134.38 M undefined-17.2 M undefined-22.42 M undefined
2018132.56 M undefined-24.1 M undefined-31.35 M undefined
2017101.52 M undefined-17.05 M undefined-19.36 M undefined
201665.98 M undefined-43.89 M undefined-51.29 M undefined
201551.65 M undefined-61.49 M undefined-61.6 M undefined
201442.5 M undefined-41.83 M undefined-41.55 M undefined
201341 M undefined-33.3 M undefined-33 M undefined
201257.9 M undefined-50.8 M undefined-53 M undefined
201166.7 M undefined-57.3 M undefined-57.6 M undefined
2010116.2 M undefined-16.5 M undefined107.6 M undefined
200926.5 M undefined-120.3 M undefined-120.7 M undefined
200811.8 M undefined-152.5 M undefined-143.5 M undefined
20077.9 M undefined-136.5 M undefined-126.8 M undefined
20067.4 M undefined-87.9 M undefined-85.1 M undefined
200530.5 M undefined-50.8 M undefined-49.6 M undefined
2004300,000 undefined-75.7 M undefined-75.5 M undefined

Basilea Pharmaceutica AG Allschwil stock margins

The Basilea Pharmaceutica AG Allschwil margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Basilea Pharmaceutica AG Allschwil. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Basilea Pharmaceutica AG Allschwil.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Basilea Pharmaceutica AG Allschwil's sales revenue. A higher gross margin percentage indicates that the Basilea Pharmaceutica AG Allschwil retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Basilea Pharmaceutica AG Allschwil's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Basilea Pharmaceutica AG Allschwil's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Basilea Pharmaceutica AG Allschwil's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Basilea Pharmaceutica AG Allschwil. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Basilea Pharmaceutica AG Allschwil's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Basilea Pharmaceutica AG Allschwil Margin History

Basilea Pharmaceutica AG Allschwil Gross marginBasilea Pharmaceutica AG Allschwil Profit marginBasilea Pharmaceutica AG Allschwil EBIT marginBasilea Pharmaceutica AG Allschwil Profit margin
2029e83 %17.27 %17.06 %
2028e83 %28.69 %28.56 %
2027e83 %34.48 %33.1 %
2026e83 %31.16 %26.96 %
2025e83 %22.95 %20.95 %
2024e83 %20.62 %25.42 %
202383 %12.18 %6.63 %
202283.35 %12.55 %8.22 %
202183.75 %0.79 %-4.61 %
202081.15 %-18.22 %-11.53 %
201985.96 %-12.8 %-16.69 %
201884.69 %-18.18 %-23.65 %
201791.11 %-16.79 %-19.07 %
201691.9 %-66.51 %-77.73 %
201583 %-119.03 %-119.26 %
201483 %-98.43 %-97.76 %
2013100 %-81.22 %-80.49 %
201292.4 %-87.74 %-91.54 %
201196.4 %-85.91 %-86.36 %
201098.02 %-14.2 %92.6 %
200993.96 %-453.96 %-455.47 %
200897.46 %-1,292.37 %-1,216.1 %
2007100 %-1,727.85 %-1,605.06 %
200683 %-1,187.84 %-1,150 %
200583 %-166.56 %-162.62 %
200483 %-25,233.33 %-25,166.67 %

Basilea Pharmaceutica AG Allschwil Aktienanalyse

What does Basilea Pharmaceutica AG Allschwil do?

Basilea Pharmaceutica AG is a leading biopharmaceutical company based in Basel, Switzerland. It was founded in 2000 and focuses on the research, development, and marketing of innovative drugs for the treatment of infectious diseases, cancer, and dermatological conditions. The company operates globally and currently employs over 200 employees. Basilea's main focus is on developing drugs that meet the specific needs of patients and medical professionals. It works closely with its partners and customers to ensure that its products meet the highest quality standards and meet the demands of patients. Basilea has two main divisions: infections and oncology. The company has a strong expertise in the development of antibiotics and antifungal drugs. One of its most well-known products is the antibiotic Ceftobiprol, which is used to treat bacterial infections such as pneumonia, skin, and bone infections. Another promising product is Isavuconazole, an antifungal drug used to treat fungal infections. In oncology, the business is divided into two important areas: the development and marketing of cancer drugs, and collaboration with other companies to develop tailored cancer therapies. The company works closely with other leading companies such as Pfizer, Roche, and GSK to expand its expertise in cancer research and development. Basilea's business model is based on the development of innovative drugs that meet the needs of patients and doctors. The company invests heavily in its research and development and aims to develop ethically sound and effective solutions for controlling infectious diseases and cancer. Through strategic partnerships and targeted marketing, it works to market its products worldwide and strengthen its position in the rapidly changing pharmaceutical market. Basilea sees itself as an innovative company that establishes itself in the market and plays a leading role in the industry. Its success is based on the concept of innovation, commitment, and growth. The company is committed to improving the quality of life for patients around the world by focusing on the development of new drugs that help fulfill important medical needs. Basilea Pharmaceutica AG remains committed to striving for excellence and innovation together with its partners and customers to advance the development of new treatment options. With this focus, Basilea will continue to play an important role in the industry and bring innovative drugs to the market that improve patients' lives and make the world a better place. Basilea Pharmaceutica AG Allschwil ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Basilea Pharmaceutica AG Allschwil's EBIT

Basilea Pharmaceutica AG Allschwil's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Basilea Pharmaceutica AG Allschwil's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Basilea Pharmaceutica AG Allschwil's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Basilea Pharmaceutica AG Allschwil’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Basilea Pharmaceutica AG Allschwil stock

How much did Basilea Pharmaceutica AG Allschwil achieve in EBIT for the current year?

In the current year, Basilea Pharmaceutica AG Allschwil has achieved an EBIT of 42.08 M CHF.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Basilea Pharmaceutica AG Allschwil.

How has the EBIT of Basilea Pharmaceutica AG Allschwil developed in recent years?

The EBIT of Basilea Pharmaceutica AG Allschwil has increased by 119.125% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Basilea Pharmaceutica AG Allschwil?

The EBIT of Basilea Pharmaceutica AG Allschwil is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Basilea Pharmaceutica AG Allschwil pay?

Over the past 12 months, Basilea Pharmaceutica AG Allschwil paid a dividend of 5 CHF . This corresponds to a dividend yield of about 12.41 %. For the coming 12 months, Basilea Pharmaceutica AG Allschwil is expected to pay a dividend of 0 CHF.

What is the dividend yield of Basilea Pharmaceutica AG Allschwil?

The current dividend yield of Basilea Pharmaceutica AG Allschwil is 12.41 %.

When does Basilea Pharmaceutica AG Allschwil pay dividends?

Basilea Pharmaceutica AG Allschwil pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Basilea Pharmaceutica AG Allschwil?

Basilea Pharmaceutica AG Allschwil paid dividends every year for the past 0 years.

What is the dividend of Basilea Pharmaceutica AG Allschwil?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is Basilea Pharmaceutica AG Allschwil located?

Basilea Pharmaceutica AG Allschwil is assigned to the 'Health' sector.

Wann musste ich die Aktien von Basilea Pharmaceutica AG Allschwil kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Basilea Pharmaceutica AG Allschwil from 6/21/2013 amounting to 5 CHF, you needed to have the stock in your portfolio before the ex-date on 4/11/2013.

When did Basilea Pharmaceutica AG Allschwil pay the last dividend?

The last dividend was paid out on 6/21/2013.

What was the dividend of Basilea Pharmaceutica AG Allschwil in the year 2023?

In the year 2023, Basilea Pharmaceutica AG Allschwil distributed 0 CHF as dividends.

In which currency does Basilea Pharmaceutica AG Allschwil pay out the dividend?

The dividends of Basilea Pharmaceutica AG Allschwil are distributed in CHF.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Basilea Pharmaceutica AG Allschwil

Our stock analysis for Basilea Pharmaceutica AG Allschwil Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Basilea Pharmaceutica AG Allschwil Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.